Cathy Eng named director for strategic relations at VICC

Long-term follow-up pinpoints side effects of prostate cancer treatments

A 10-year follow-up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision-making in terms of treatments and side effects for a diverse population.

January 26, 2024

Vol.50 No.04

Clinical Roundup

Molecular profiles of tissue plus circulating tumor DNA can better guide cancer care

The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.

January 26, 2024

Vol.50 No.04

In Brief

W. Kimryn Rathmell installed as 17th NCI director

W. Kimryn Rathmell was installed as the 17th director of NCI on Dec. 18, 2023.

January 05, 2024

Vol.50 No.01

Vinay Prasad describes his Vanderbilt colleagues as “despicable,” raising new questions about physicians’ conduct on social media

At a time when distinguished careers can falter because of a careless Facebook post, the oncologist-iconoclast Vinay Prasad is showing no sign of moderating the shaming and haranguing that make him a social media phenom.

December 01, 2023

Vol.49 No.44

By Paul Goldberg

Conversation with The Cancer Letter

Prasad could not have had patient data when he called Vanderbilt colleagues “despicable”

Vinay Prasad, a social media phenom and professor of epidemiology and biostatistics at the University of California, San Francisco, recently stunned his colleagues by stating that doctors at Vanderbilt University acted in a “despicable” manner when they offered a double lung transplant to a lung cancer patient. “The doctors at Vanderbilt are despicable in my...

December 01, 2023

Vol.49 No.44

By Paul Goldberg